These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 7302889)

  • 1. Antithrombin III, the major modulator of intravascular coagulation, is synthesized by human endothelial cells.
    Chan TK; Chan V
    Thromb Haemost; 1981 Aug; 46(2):504-6. PubMed ID: 7302889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactivity of a hereditary abnormal antithrombin III fraction in the inhibition of thrombin and factor Xa.
    Tran TH; Bondeli C; Marbet GA; Duckert F
    Thromb Haemost; 1980 Oct; 44(2):92-5. PubMed ID: 7455997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of pentosan polysulphate (SP54) and heparin. I: Mechanism of action on blood coagulation.
    Fischer AM; Barrowcliffe TW; Thomas DP
    Thromb Haemost; 1982 Apr; 47(2):104-8. PubMed ID: 6179182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formation of activated protein C and inactivation of cell-bound thrombin by antithrombin III at the surface of cultured vascular endothelial cells--a comparative study of two anticoagulant mechanisms.
    Delvos U; Meusel P; Preissner KT; Müller-Berghaus G
    Thromb Haemost; 1987 Feb; 57(1):87-91. PubMed ID: 3590084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombin III Geneva: a hereditary abnormal AT III with defective heparin cofactor activity.
    de Moerloose PA; Reber G; Vernet P; Minazio P; Bouvier CA
    Thromb Haemost; 1987 Apr; 57(2):154-7. PubMed ID: 3603409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The characteristics of anticoagulation by covalently immobilized heparin.
    Miura Y; Aoyagi S; Kusada Y; Miyamoto K
    J Biomed Mater Res; 1980 Sep; 14(5):619-30. PubMed ID: 7349668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homozygous variant of antithrombin III that lacks affinity for heparin, AT III Kumamoto.
    Okajima K; Ueyama H; Hashimoto Y; Sasaki Y; Matsumoto K; Okabe H; Inoue M; Araki S; Takatsuki K
    Thromb Haemost; 1989 Feb; 61(1):20-4. PubMed ID: 2749590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of thrombin and factor Xa with bovine vascular endothelial cells, smooth muscle cells and rat hepatoma cells.
    Dryjski M; Kuo BS; Bjornsson TD
    Thromb Haemost; 1988 Oct; 60(2):148-52. PubMed ID: 3217915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombin-induced proteolysis of human antithrombin III: an outstanding contribution of heparin.
    Marciniak E
    Br J Haematol; 1981 Jun; 48(2):325-36. PubMed ID: 7236529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor.
    Ofosu FA; Cerskus AL; Hirsh J; Smith LM; Modi GJ; Blajchman MA
    Br J Haematol; 1984 Jun; 57(2):229-38. PubMed ID: 6733045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of an abnormal antithrombin (Milano 2) with defective thrombin binding.
    Tripodi A; Krachmalnicoff A; Mannucci PM
    Thromb Haemost; 1986 Dec; 56(3):349-52. PubMed ID: 3563966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical and functional study of antithrombin III in newborn infants.
    McDonald MM; Hathaway WE; Reeve EB; Leonard BD
    Thromb Haemost; 1982 Feb; 47(1):56-8. PubMed ID: 7071806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical considerations on the measurement of low molecular weight heparin anti-Xa activity.
    Aiach M; Roncato M
    Semin Thromb Hemost; 1985 Apr; 11(2):108-11. PubMed ID: 4035362
    [No Abstract]   [Full Text] [Related]  

  • 14. Anticoagulant activity of artificial biomedical materials with co-immobilized antithrombin III and heparin.
    Miura Y; Aoyagi S; Ikeda F; Miyamoto K
    Biochimie; 1980; 62(8-9):595-601. PubMed ID: 7417594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of a sulfated polysaccharide on antithrombin III.
    Czapek EE; Kwaan HC; Szczecinski M
    J Lab Clin Med; 1980 Jun; 95(6):783-90. PubMed ID: 6155418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular weight of heparin versus biologic activity. Some additional considerations.
    Losito R; Losito C
    Semin Thromb Hemost; 1985 Jan; 11(1):29-33. PubMed ID: 2579437
    [No Abstract]   [Full Text] [Related]  

  • 17. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence.
    Bohner J; von Pape KW; Blaurock M
    Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homozygous variant of antithrombin III: AT III Fontainebleau.
    Boyer C; Wolf M; Vedrenne J; Meyer D; Larrieu MJ
    Thromb Haemost; 1986 Aug; 56(1):18-22. PubMed ID: 3775688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-clinical pharmacological profile of the novel glycoconjugate Org 36764 with both factor Xa and thrombin (IIa) inhibitory activities.
    Vogel GM; van Amsterdam RG; van Dinther TG; Tromp M; Meuleman DG
    Thromb Haemost; 2000 Oct; 84(4):611-20. PubMed ID: 11057859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and characterization of recombinant human antithrombin III in Pichia pastoris.
    Mochizuki S; Hamato N; Hirose M; Miyano K; Ohtani W; Kameyama S; Kuwae S; Tokuyama T; Ohi H
    Protein Expr Purif; 2001 Oct; 23(1):55-65. PubMed ID: 11570846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.